Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

coplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's operations and financial condition, business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Hill-Rom (NYSE: HRC ) today announced a ... WA ), the nation,s third largest not-for-profit health ... as Hill-Rom now becomes Providence Health,s sole-source provider of ... surface products. Providence Health is one ... operates 34 hospitals, 475 physician clinics, 22 long-term care ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... , Sept. 23, 2014   COTA, Inc. ... planned $7 million Series A funding round led by ... COTA is the first big data platform designed by ... cost analysis for cancer care in support of healthcare,s ... used to expand development of the COTA platform, hire ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
... DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc. ... and dermatology, today announced that a catheter,treated ... biofilm,formation in a 21 day study., In ... soaked daily in a phosphate-suffered solution along ...
Cached Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:9/23/2014)... 2014 Avid collector Andrew Hawley, from Vintage ... Eagle Auditorium Seattle concert posters. The Doors were a smash ... that year. The Seattle Eagles Auditorium concert was held on ... return to Eagles Auditorium in November the same year. The ... and comes in three colors. The poster is a split ...
(Date:9/23/2014)... 2014 What: Rutgers Presbyterian Church, ... Side that embodies the inclusion and diversity of ... and the Ecological Crisis, a public lecture led ... Emerita of Old Testament at Louisville Presbyterian Seminary. ... that lends insight into current ecological problems, including ...
(Date:9/23/2014)... Oregon survey about an exercise DVD that adds short ... elementary school students found it had a high level ... clear advantages for overly sedentary educational programs. , Called ... the Healthy Youth Program of the Linus Pauling Institute ... Brain Breaks leads children in 5-7 minute segments of ...
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... September 23, 2014 The ... rhinitis (AR) is highly fragmented, with the ... formulations available, under different regulatory restrictions, with ... Europe has the most developed market, with ... allergen immunotherapy tablets (AITs) all being available. ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... Increase for Small Business Owners at ... http://www.bluecrossca.com/click4biz , THOUSAND OAKS, Calif., ... fastest growing segments of California,s economy, however,many small business owners ... Blue Cross of California has just made it,easier for small ...
... vitamins and minerals does not seem to prevent the degenerative ... study published on bmj.com today. , Age related ... older people. It is caused by the progressive break down ... centre of the retina at the back of the eye. ...
... 8 Proposed,regulations that would govern who owns ... grants to for-profit organizations fail,to ensure affordable access ... for the research, the Foundation for Taxpayer and ... the people who have paid for the research ...
... Saturn, committed to health, fitness,and healthy living in communities ... health and fitness expo, held in conjunction with the ... Saturn Health and Fitness Expo, which runs Oct. 19-20 ... vendors,informational booths and groups that provide services to runners. ...
... 8 - The Washington,State Veterinary Medical Association awarded ... veterinarian with Olympia Pet,Emergency in Lacey. (Logo: ... his award in recognition of his dedication to,organized ... Washington,State University,s College of Veterinary Medicine, he has ...
... Help ... Owners Cope, SACRAMENTO, Calif., Oct. ... and language skills died last,month, his owner, scientist Irene Pepperberg, needed time ... it. Newspapers and web,sites printed his obituary and many people sent condolences. ...
Cached Medicine News:Health News:New Online Tool Makes Enrollment in Blue Cross of California Easier 2Health News:Antioxidants do not prevent degenerative eye disease 2Health News:Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn 2Health News:Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon 2Health News:Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award 2Health News:We Love Our Pets and Grieve When They Die 2Health News:We Love Our Pets and Grieve When They Die 3
... Retinol binding Proetin (RBP) is small ... a complex with pre-albumin in blood but ... has been deliverd to the target cells. ... at the glomerulus and catabolized in the,renal ...
... is an enzyme immunoassay (EIA) kit for ... of the subclass of Anti-Neutrophil Cytoplasmic Antibodies ... as an aid in the diagnosis of ... associated with vasculitic disorders and glomerulonephritis (GN). ...
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: